UNICHEMLAB · Unichem Laboratories Ltd · Major Drugs
UNICHEMLAB · Unichem Laboratories Ltd · Major Drugs
As of 05 Nov close
52-week range
28.2% below 52-week high
52-week range: as of 05 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 15 Sep 2026 · the company's own latest record is 52 days old
Revenue (latest Q)
₹633 Cr
Revenue YoY
PAT YoY
+496.1%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
1.3
P/S (TTM)
1.7
Sector P/E
36.3
Dividend yield
0.0%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| UNICHEMLAB (this stock) | 10.7 | 1.3 | +13.2% | +11.2% | 0.18 | 0.0% |
| Aurobindo Pharma | 24.7 | 2.9 | +10.6% | +9.8% | 0.21 | 0.0% |
| Neuland Laboratories | 64.3 | 12.6 | +18.0% | +21.4% | 13.9 | +0.2% |
| Pfizer | 27.6 | 5.1 | +28.6% | +17.5% | 0.02 | +1.9% |
Promoter
stable
FII
falling 1q
MF
9.32% (+0.25pp)
rising 1q
Insider trades
No insider trades in the last 12 months.
Bulk/block deals
| canonicalSymbol | date | buy quantity | buyer count | deal strength | deal types present |
|---|---|---|---|---|---|
| UNICHEMLAB | 2026-07-09 | 600901 | 1 | STRONG | BULK |
| UNICHEMLAB | 2026-06-11 | 5302409 | 7 | WEAK | BULK |
News timeline
No related news.
Concalls & investor presentations
AI-generatedNo concall transcripts or investor presentations recorded yet.
AI Summary of Annual Report
AI-generatedUnichem Laboratories Limited reported a 4.31% increase in consolidated revenue to ₹2,201.85 crores in FY2025-26, though profit before tax declined to ₹90.52 crores from ₹154.59 crores. The company faces risks related to asset impairment, with ₹1,289.98 crores in property, plant, and equipment at risk. A contingent liability of €19.55 million was settled in October 2025, and there are ongoing disputes over GST, excise, and income tax dues. The auditor highlighted significant judgment in impairment assessments and noted a stable credit rating of A+ from ICRA. The company is expanding its API business and strategic partnerships but faces pricing pressures in emerging markets.
- Consolidated revenue grew by 4.31% to ₹2,201.85 crores in FY2025-26.
- Profit before tax declined to ₹90.52 crores from ₹154.59 crores.
- ₹1,289.98 crores in property, plant, and equipment are at risk of impairment.
- A contingent liability of €19.55 million related to EU fines was settled in October 2025.
- Ongoing disputes over GST, excise, and income tax dues remain unresolved.
Key takeaway: Unichem Laboratories Limited shows revenue growth but faces challenges in profitability, asset impairment risks, and unresolved tax disputes.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
Default / Covenant Breach (1 item)
Items of these kinds are disclosed in the filings. This is a count of disclosed items. It is not a finding about the company and its cause has not been independently established.
Default / Covenant Breach
1 occurrenceEarlier (1-3 years ago)
The company has statutory dues pending for more than six months as of 31st March 2025, with disputes over amounts under various tax acts, including GST and service tax, with specific amounts and periods noted.
Routine disclosures
Contingent Liability
2 occurrencesRecent (last 12 months)
The company has received a demand order from the European Commission for a fine and interest totaling Euro 19.55 million, which was fully settled by October 2025. A provision of Euro 13.96 million was recognized in the 2023-2024 financial year.
Earlier (1-3 years ago)
The company has a contingent liability of ₹67.82 crores related to its subsidiary Niche Generic Limited, including outstanding trade receivables and a corporate guarantee given to a bank on behalf of the subsidiary.
Related-Party Transaction
2 occurrencesRecent (last 12 months)
The company conducted a postal ballot seeking approval for material related party transactions between Ipca, the holding company of Unichem, and Unichem USA, a wholly owned subsidiary of Unichem.
Earlier (1-3 years ago)
The company approved a resolution to allow the Board of Directors to enter into or continue transactions between Ipca Laboratories Limited, Unichem Laboratories Limited, and Unichem Pharmaceuticals (USA) Inc., which are related parties.
Statutory dues in dispute
1 occurrenceRecent (last 12 months)
The company has unpaid statutory dues under various acts including GST, Excise, and Income Tax, with disputes pending in multiple forums, as of 31st March 2026.
Promoter Share Pledge
1 occurrenceRecent (last 12 months)
0.78% of promoter holding pledged (quarter 2026-Q3 as of 2026-07-18).